ADC“Biological Missile” Production Code Series Ⅱ | ADC Preparation & Storage Under Solvent Challenges: Chemical Compatibility Strength of Single‑Use Mixing/Storage Bags

Manufacturing and developing ADC drugs is akin to walking on a knife‑edge.

On one hand, high DAR values are pursued for potent cytotoxic effects;

On the other hand, highly hydrophobic payload small molecules require substantial volumes of organic solvents — such as DMSO (dimethyl sulfoxide), DMAC (dimethylacetamide), and DMF (dimethylformamide) — to achieve dissolution during production.

When these aggressive solvents come into contact with single‑use mixing/storage systems, a stark reality emerges:

Leaking bags are not the greatest hazard. The real risk lies in invisible leachables that can silently compromise your ADC drug, or worse, enter patients alongside drug solutions.

Within ADC preparation and storage workflows, chemical compatibility is no longer an optional quality criterion — it is the lifeline for safe manufacturing.

In‑Depth Breakdown: Core Challenges for ADC Preparation & Storage

Key manufacturing bottlenecks for ADC drugs stem from solvent‑intense conjugation processes and complex formulation storage systems, which also represent the biggest hurdles for consumable adaption:

1.Attack by highly permeable organic solvents: Dissolving ADC payloads and linkers often employs 10‑50 % concentrations of penetrating organic solvents including DMSO and DMAC. Such solvents readily permeate conventional plastic films, causing material swelling, extractables release, and structural failure. This contaminates process fluids and impairs ADC conjugation efficiency and product purity.

2.Extreme pH and complex buffer matrices: ADC preparation and storage involve acidic buffers at pH 3.0 and alkaline buffers at pH 10.0. Prolonged exposure degrades ordinary consumables and generates sub‑visible particles.

3.Demanding long‑term storage stability: ADC intermediates and drug substance require extended static storage. Chronic material‑solvent interactions create hidden quality risks, placing stringent demands on consumable bioinertness and chemical stability.

4.Mandatory data compliance and safety: As high‑value premium therapeutics, ADC production must satisfy GMP, 21 CFR Part 11, USP <665> and other regulatory requirements. Complete, controlled datasets for consumable extractables, particles and biocompatibility are compulsory.

Robust Assurance: Three‑Tier Performance Safeguard to Secure Chemical Safety for ADC Preparation & Storage

To address harsh solvent conditions in ADC workflows, BioLink BioHub® Single‑Use Mixing/Storage bags are engineered from fundamental molecular‑level chemistry, re‑defining resistance to aggressive solvents. Three robust protective layers deliver exceptional chemical compatibility.

Figure 1: BioHub® Single‑Use Mixing Bag

Tier 1 | High‑Purity ULDPE Inner Layer: Intrinsic Chemical Inertness Against Harsh ADC Solvents

The fluid‑contact surfaces of BioLink’s two flagship films (FirmaX® S32 / Renolit 9101) adopt ULDPE (ultra‑low‑density polyethylene). Unlike standard PE and EVA substrates, this starting material delivers inherent chemical inertness:

EVA contains vinyl acetate linkages that undergo saponification in strong alkali and exhibit severe swelling in DMSO/DMAC, rendering it unsuitable for ADC conjugation workflows.

Conventional PE has high crystallinity, enabling high‑strength organic solvents to penetrate the matrix and leach processing additives.

ULDPE features no readily hydrolysable ester bonds and minimal formulation additives. It demonstrates stable resistance to DMSO, DMAC, concentrated acids‑bases, and high‑strength surfactants without swelling, whitening, or substrate degradation. It prevents solvent‑driven corrosion and fluid contamination at the point‑of‑contact, supporting demanding payload dissolution and conjugation workflows. Raw materials are animal‑origin‑free and BSE/TSE‑compliant to eliminate hidden extractable impurities.

Figures 2 & 3: Schematic Structure of FirmaX® S32 / Renolit 9101 Film

Tier 2 | Authoritative Extractables Testing: Extreme‑Solvent Benchmarking for Injectable‑Grade Safety

Extractables constitute a non‑negotiable acceptance criterion for injectable‑grade ADC consumables. BioLink strictly follows USP <665>, BPOG and ICH Q3D. Dynamic cyclic extraction is performed with multiple solvents under stressed conditions at 40 °C. GC‑MS, LC‑DAD‑QTOF and ICP‑MS characterize organic and inorganic extractables. Testing covers all additive categories flagged for caution in the Technical Guiding Principles for Compatibility Studies of Chemical Drugs with Elastomeric Seals (Trial).

Test results confirm that extractables from BioLink BioHub® Single‑Use Mixing/Storage Bags under BPOG and USP <665> conditions fall within compound‑specific PDE (permitted daily exposure) limits, confirming favourable extractables profiles and product safety.

Table 1: Extractables Profile of FirmaX® S32 / Renolit 9101 Film

Tier 3 | Full‑Spectrum Compatibility Datasets: Hundreds‑of‑Reagent Benchmarking Covering Complete ADC Formulation Space

30‑day immersion validation for hundreds of biochemical reagents is executed per ASTM D543 to build a comprehensive chemical‑compatibility database.

Organic solvents: graded R compatibility across concentration ranges for ethanol, isopropanol, DMSO and DMAC.

Acids, bases and salts: stable long‑term immersion with sodium hydroxide, phosphate‑citrate buffers, guanidine hydrochloride and saturated sodium chloride.

Formulation excipients: full compatibility with ADC‑relevant excipients including Tween 20/80, imidazole, EDTA and glycine.

Separate performance ratings are assigned for films, silicone, TPE, PP and PVDF components. Custom tubing‑fitting assemblies can be configured per end‑user formulations to mitigate material‑specific incompatibility risks.

Table 2: Chemical‑Compatibility Test Results for BioHub® Single‑Use Mixing/Storage Bag Films, Tubing and Fittings

Legend for Table 2:

• R: Negligible or acceptable interaction following 30‑day contact

• R1: Negligible or acceptable interaction following 7‑day contact

• R2: Negligible or acceptable interaction following 1‑day contact

• NR: Interaction observed

• LR: Restricted use at room temperature for up to 30 days; end‑user pre‑testing recommended

• —: Not tested

Application Coverage: End‑to‑End ADC Preparation & Storage Workflows

Superior chemical compatibility paired with flexible product design enables BioHub® Single‑uUse Mixing/Storage Bags to serve ADC drug discovery, process scaling and GMP‑compliant commercial manufacturing:

Conjugation unit operations: Intermediate preparation and hold under DMSO/DMAC organic‑solvent conditions, mitigating solvent‑induced consumable‑related quality risks.

Buffer preparation: Formulation and storage of high‑/low‑pH multi‑salt buffers with no precipitation.

Drug‑substance storage: Long‑term sterile hold of post‑conjugate ADC drug substance and purified intermediates to preserve product potency.

Formulation filling: Final drug‑product mixing and transfer, maintaining high‑level cleanliness to meet rigorous finished‑product quality specifications.

Quality Assurance: End‑to‑End Controllability for Commercial‑Scale Manufacturing

Beyond core performance attributes, BioLink controls product quality from raw‑material intake to match high‑end ADC production requirements:

Comprehensive compliance: ISO 9001 and ISO 13485 certified; FDA Type III DMF filed to streamline pharmaceutical registration submissions.

Stringent manufacturing: Produced within ISO Class 7 cleanrooms; 100 % visual inspection and 100 % integrity testing to eliminate factory‑out defects.

Full traceability: Raw‑material, production, testing and release records retained for ≥5 years with precise batch traceability to satisfy GMP audit expectations.

Customization capability: Standard volumes from 10 L to 3000 L. Custom ports, tubing and sensor interfaces available to accommodate diverse throughput and formulation requirements.

Closing Remarks: Material Selection Safeguards Product Safety

Quality breakthroughs for ADC therapeutics originate from meticulous process details. Faced with harsh solvent environments, consumable chemical compatibility is no longer a competitive advantage — it represents the fundamental baseline for secure, reliable drug manufacturing.

BioLink BioHub® Single‑Use Mixing/Storage Bags leverage premium film substrates, authoritative validation, broad application adaptability and compliance‑oriented quality to resolve solvent‑compatibility challenges in ADC preparation and storage. The solution effectively mitigates fluid contamination, potency loss and regulatory exposure, supporting innovative R&D and large‑scale commercialization of domestic ADC therapeutics through robust single‑use process technologies.

BioLink — Dedicated to R&D and manufacturing of bioprocess consumables and equipment, empowering high‑quality development of the biopharmaceutical industry through differentiated product excellence.